ImageneBio (IMA) Restructuring Costs (2024 - 2025)
ImageneBio (IMA) posted Restructuring Costs of $2.8 million for Q3 2025, up 822.01% sequentially from $309000.0 in Q2 2025, and up 586.51% YoY from $415000.0 in Q3 2024.
ImageneBio (IMA) Restructuring Costs (2024 - 2025) Analysis & Trends
ImageneBio has reported Restructuring Costs for 2 years, with the latest figure at $2.8 million in Q3 2025.
- Quarterly Restructuring Costs rose 586.51% year-over-year to $2.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.1 million (changed N/A YoY) and the FY2024 annual result came in at $1.8 million, changed N/A from the prior year.
- Restructuring Costs rose to $2.8 million in Q3 2025 per IMA's latest filing, from $309000.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $2.8 million in Q3 2025 and troughed at -$541000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.85 Mn |
| Jun 30, 2025 | 309,000.00 |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | -541,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Jun 30, 2024 | 683,000.00 |
| Mar 31, 2024 | 2.60 Mn |